Czibere Akos
Known title: Chief Medical OfficerCIK: 0002049427
Associated companies
Transaction History
| AKTS | ▲ Buy | Option Exercise | 12,500 | $62K | 9/23/2026 | View on chart |
| AKTS | ▼ Sell | Open Market | 5,099 | $103K | 9/23/2026 | View on chart |
| AKTS | ▼ Sell | Open Market | 7,401 | $156K | 9/23/2026 | View on chart |
| AKTS | ▲ Buy | Option Exercise | 50,000 | $248K | 7/8/2026 | View on chart |
| AKTS | ▼ Sell | Open Market | 14,800 | $401K | 7/8/2026 | View on chart |
| AKTS | ▼ Sell | Open Market | 30,829 | $862K | 7/8/2026 | View on chart |
| AKTS | ▼ Sell | Open Market | 4,371 | $125K | 7/8/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AKTS launches second Phase 1b trial for AKY-2519
Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.
AKTS launches second Phase 1b trial for AKY-2519. Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.